@prefix this: . @prefix sub: . @prefix np: . @prefix pav: . @prefix rdf: . @prefix infores: . @prefix xsd: . @prefix umls: . @prefix orcid: . @prefix rdfs: . @prefix biolink: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubInfo; a np:Nanopublication . } sub:assertion { a biolink:ChemicalEntity; rdfs:label "Ivabradine"; biolink:category biolink:ChemicalEntity . umls:C1299487 a biolink:OrganismTaxon; rdfs:label "patients"; biolink:category biolink:OrganismTaxon . a biolink:DiseaseOrPhenotypicFeature; rdfs:label "heart failure"; biolink:category biolink:DiseaseOrPhenotypicFeature . a biolink:DiseaseOrPhenotypicFeature; rdfs:label "dilated cardiomyopathy"; biolink:category biolink:DiseaseOrPhenotypicFeature . sub:_1 rdf:object ; rdf:predicate biolink:treats; rdf:subject ; a biolink:Association; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications . sub:_2 rdf:object ; rdf:predicate biolink:treats; rdf:subject ; a biolink:Association; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications . sub:_3 rdf:object ; rdf:predicate biolink:treats; rdf:subject ; a biolink:Association; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications . sub:_4 rdf:object ; rdf:predicate biolink:treats; rdf:subject ; a biolink:Association; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications . } sub:provenance { sub:assertion prov:generatedAtTime "2022-10-11T09:43:22.630727"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0002-3668-2627; prov:wasQuotedFrom " Ivabradine is indicated by the FDA to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure. It is also indicated for treatment of stable symptomatic heart failure as a result of dilated cardiomyopathy for pediatric patients 6 months of age or more. The drug is indicated for patients with left ventricular ejection fraction of less than 35%." . biolink: pav:version "2.3.0" . } sub:pubInfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIIBIjANBgkqhkiG9w0BAQEFAAOCAQ8AMIIBCgKCAQEApdULbl+/+pkVlq0fAzWmzfgIb+XMuQPKHMDVzUTWCZBjLfzORll42ptr52e4w7tTYkUKrBsQbx8lkjZWAlWiyh+xIK0oLFSdYRSt63kgiyRYBUOR+spcgmofb7f6JyftArPVTKhsWOMt/mcyNG9qc3lw8B/xuPmLteUWO33xWhfXQreTw1lsGUkZ1j4cB4X9HIuI20ktLYLCXaBauNHEJZ4qp6/Q2ATsJcw8tg7aRmFKXhrjM9maZ2+0cMg0Jpmn2UnDlPKXEA6Qq+qnvvQt8KFjIzP9FTMyvrWl8tTd0NCmS9VpooZJQ8We1lGMPXg5bMbe/bVkTf70fbFMf0RKrQIDAQAB"; npx:hasSignature "TdnQHB0Y79c/LFt7Yt18dPDvKVBMY5ffQVkFhGehXJu1il32yZFXm7A20RfqrseWSK5ntGC+1Z9hjAS6nmh6I0i3D2zg1QcdRndL+jEg+dYen6rCNA5EVVxENjw6/upkl4XQtjRv4qzWDel5jJOgvznsvF7YdhA5SOb5iWsxRi6EbqBi6LWa/O/k6U4lzdvlmWKIeZdORpZfBhn8fINPChEVk7eHmrEaSlWDpjMoCRMBJW9InrgEnCytVeN3eKO1NT6ASiQNdBNQJjdmxBSYohcvRRYgOpoprS8IhSAh1+Z0D69tJNEC3Gz+WafCXz+Auuz8lR7j31bUm1lieT0MWg=="; npx:hasSignatureTarget this: . this: prov:generatedAtTime "2022-10-11T09:43:22.630727"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0002-3668-2627 . }